New Zealand markets open in 2 hours 58 minutes

ImmunoPrecise Antibodies Ltd. (IPA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.44+0.03 (+0.55%)
As of 12:57PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 105.77M
Enterprise value 76.60M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.16
Price/book (mrq)2.42
Enterprise value/revenue N/A
Enterprise value/EBITDA -18.30

Trading information

Stock price history

Beta (5Y monthly) -0.16
52-week change 3-28.72%
S&P500 52-week change 322.93%
52-week high 333.34
52-week low 35.05
50-day moving average 36.09
200-day moving average 37.83

Share statistics

Avg vol (3-month) 374.14k
Avg vol (10-day) 397.89k
Shares outstanding 519.37M
Implied shares outstanding 6N/A
Float 818.01M
% held by insiders 16.91%
% held by institutions 16.76%
Shares short (14 Nov 2021) 4292.48k
Short ratio (14 Nov 2021) 46.3
Short % of float (14 Nov 2021) 4N/A
Short % of shares outstanding (14 Nov 2021) 41.51%
Shares short (prior month 14 Oct 2021) 4454.05k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Nov 2020
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 322 Nov 2020

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 29 Apr 2021
Most-recent quarter (mrq)30 Jul 2021

Profitability

Profit margin -53.49%
Operating margin (ttm)-49.62%

Management effectiveness

Return on assets (ttm)-11.88%
Return on equity (ttm)-26.60%

Income statement

Revenue (ttm)18.73M
Revenue per share (ttm)1.06
Quarterly revenue growth (yoy)21.90%
Gross profit (ttm)11.4M
EBITDA -7.6M
Net income avi to common (ttm)-10.02M
Diluted EPS (ttm)-0.44
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)40.7M
Total cash per share (mrq)2.1
Total debt (mrq)3.29M
Total debt/equity (mrq)5.93
Current ratio (mrq)7.08
Book value per share (mrq)2.88

Cash flow statement

Operating cash flow (ttm)-1.97M
Levered free cash flow (ttm)-2.05M